Incremental prognostic and risk-stratification value of ultrasound-based Carotid Plaque Reporting and Data System (Plaque-RADS) classification for recurrent ischemic stroke in patients with low-to-moderate-grade carotid stenosis.
- 1Department of Ultrasound, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Abstract
The Carotid Plaque Reporting and Data System (Plaque-RADS) is a system for stroke risk assessment. However, the clinical utility of ultrasound (US)-based Plaque-RADS remains unclear. This study aimed to assess the incremental prognostic value and risk stratification utility of US-based Plaque-RADS in patients with prior stroke and low-to-moderate-grade carotid stenosis. Between January 2020 and December 2022, 231 patients with carotid plaque ipsilateral to the prior stroke and low-to-moderate-grade carotid stenosis were retrospectively screened, of whom 158 were included in the final analysis. US-based Plaque-RADS classification was assigned based on duplex US assessment of plaque features. Cox regression and subgroup analyses were performed to evaluate the association between high-risk US-based Plaque-RADS categories and recurrent ischemic stroke. Model discrimination was assessed using receiver operating characteristic curves and area under the curve (AUC), and clinical utility was evaluated using decision curve analysis. The association between increasing US-based Plaque-RADS categories and the risk of recurrent ischemic stroke was assessed by trend analysis. The incremental risk-stratification value of refined high-risk Plaque-RADS thresholds was quantified with net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Internal validation was performed using bootstrap resampling. During the 3-year follow-up period, recurrent ischemic stroke occurred in 33 patients. High-risk US-based Plaque-RADS categories were significantly associated with recurrent ischemic stroke in patients with prior stroke and low-to-moderate-grade carotid stenosis, after adjusting for smoking, homocysteine, and intraplaque neovascularization [adjusted hazard ratio: 3.56; 95% confidence interval (CI): 1.07-11.83, P=0.038]. No statistically significant interactions were observed across the subgroups (all P for interaction >0.05). The Plaque-RADS ≥3 model demonstrated a higher AUC than the conventional US model [0.816 (95% CI: 0.731-0.901) vs. 0.810 (95% CI: 0.720-0.899)] and provided a slight net benefit across selected threshold probabilities. Additionally, the risk of recurrent ischemic stroke increased with higher Plaque-RADS categories (P for trend <0.001). Among the models using different high-risk Plaque-RADS thresholds, the Plaque-RADS ≥3b model showed the best predictive performance (0.865, 95% CI: 0.799-0.930), compared with the Plaque-RADS ≥3 model and the Plaque-RADS ≥3c model [0.824 (95% CI: 0.740-0.906)]. The Plaque-RADS ≥3b model also showed moderate improvements in NRI [0.250; (95% CI: 0.088-0.557), P=0.017] and IDI [0.090; (95% CI: 0.000-0.185), P=0.049], compared with the Plaque-RADS ≥3 model. Bootstrap internal validation indicated limited optimism across all models. In patients with prior stroke and low-to-moderate-grade carotid stenosis, high-risk US-based Plaque-RADS categories were significantly associated with recurrent ischemic stroke. The US-based Plaque-RADS may help identify plaque phenotypes associated with an increased risk of recurrent ipsilateral ischemic stroke, while refined high-risk thresholds, particularly Plaque-RADS ≥3b, may provide additional value for risk stratification.
Related
- Incremental Value of Radiation Dose for Prognostic Stratification Beyond Performance Status in Palliative Radiation Therapy for Bone Metastases
- RAS Mutations as Prognostic Biomarkers in Digestive Cancers: From Binary Classification to Variant-Specific and Context-Dependent Risk Stratification
- Beyond Molecular Classification: The Incremental Value of Prognostic Biomarkers in Endometrial Cancer
- An immunogenic cell death-related classification for prognostic stratification and immunotherapy response prediction in proficient mismatch repair/microsatellite stable colorectal cancer.
- Multimodal integration of carotid plaque ultrasound radiomics and dynamic systemic immune-inflammation trajectories for subacute risk stratification after stroke thrombectomy: development and internal validation of an exploratory prognostic model
BibTeX
@article{che2026incremental,
title = {{Incremental prognostic and risk-stratification value of ultrasound-based Carotid Plaque Reporting and Data System (Plaque-RADS) classification for recurrent ischemic stroke in patients with low-to-moderate-grade carotid stenosis.}},
author = {Yujie Che and Yukang Zhang and Linyu Xu and Sen Wang and Yiqun Lin and Juying Zhang and Wei Zhang and Wen He},
journal = {Quantitative imaging in medicine and surgery},
year = {2026},
month = sep,
doi = {10.21037/qims-2026-1216},
url = {https://europepmc.org/article/MED/42997941},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Incremental prognostic and risk-stratification value of ultrasound-based Carotid Plaque Reporting and Data System (Plaque-RADS) classification for recurrent ischemic stroke in patients with low-to-moderate-grade carotid stenosis.
AU - Yujie Che
AU - Yukang Zhang
AU - Linyu Xu
AU - Sen Wang
AU - Yiqun Lin
AU - Juying Zhang
AU - Wei Zhang
AU - Wen He
PY - 2026
DA - 2026/09/30
JO - Quantitative imaging in medicine and surgery
DO - 10.21037/qims-2026-1216
UR - https://europepmc.org/article/MED/42997941
AB - The Carotid Plaque Reporting and Data System (Plaque-RADS) is a system for stroke risk assessment. However, the clinical utility of ultrasound (US)-based Plaque-RADS remains unclear. This study aimed to assess the incremental prognostic value and risk stratification utility of US-based Plaque-RADS in patients with prior stroke and low-to-moderate-grade carotid stenosis. Between January 2020 and December 2022, 231 patients with carotid plaque ipsilateral to the prior stroke and low-to-moderate-grade carotid stenosis were retrospectively screened, of whom 158 were included in the final analysis. US-based Plaque-RADS classification was assigned based on duplex US assessment of plaque features. Cox regression and subgroup analyses were performed to evaluate the association between high-risk US-based Plaque-RADS categories and recurrent ischemic stroke. Model discrimination was assessed using receiver operating characteristic curves and area under the curve (AUC), and clinical utility was evaluated using decision curve analysis. The association between increasing US-based Plaque-RADS categories and the risk of recurrent ischemic stroke was assessed by trend analysis. The incremental risk-stratification value of refined high-risk Plaque-RADS thresholds was quantified with net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Internal validation was performed using bootstrap resampling. During the 3-year follow-up period, recurrent ischemic stroke occurred in 33 patients. High-risk US-based Plaque-RADS categories were significantly associated with recurrent ischemic stroke in patients with prior stroke and low-to-moderate-grade carotid stenosis, after adjusting for smoking, homocysteine, and intraplaque neovascularization [adjusted hazard ratio: 3.56; 95% confidence interval (CI): 1.07-11.83, P=0.038]. No statistically significant interactions were observed across the subgroups (all P for interaction >0.05). The Plaque-RADS ≥3 model demonstrated a higher AUC than the conventional US model [0.816 (95% CI: 0.731-0.901) vs. 0.810 (95% CI: 0.720-0.899)] and provided a slight net benefit across selected threshold probabilities. Additionally, the risk of recurrent ischemic stroke increased with higher Plaque-RADS categories (P for trend <0.001). Among the models using different high-risk Plaque-RADS thresholds, the Plaque-RADS ≥3b model showed the best predictive performance (0.865, 95% CI: 0.799-0.930), compared with the Plaque-RADS ≥3 model and the Plaque-RADS ≥3c model [0.824 (95% CI: 0.740-0.906)]. The Plaque-RADS ≥3b model also showed moderate improvements in NRI [0.250; (95% CI: 0.088-0.557), P=0.017] and IDI [0.090; (95% CI: 0.000-0.185), P=0.049], compared with the Plaque-RADS ≥3 model. Bootstrap internal validation indicated limited optimism across all models. In patients with prior stroke and low-to-moderate-grade carotid stenosis, high-risk US-based Plaque-RADS categories were significantly associated with recurrent ischemic stroke. The US-based Plaque-RADS may help identify plaque phenotypes associated with an increased risk of recurrent ipsilateral ischemic stroke, while refined high-risk thresholds, particularly Plaque-RADS ≥3b, may provide additional value for risk stratification.
SN - 2223-4292
SN - 2223-4306
ER -